Skip to content
Synopulse
  • The Brief
    • Quick
    • In Depth
    • Editor’s Pick
    • Findings
  • Reports
    • The beats
      • Catalyst
      • AccessWatch
      • DealPulse Signal
      • DealPulse Report
    • Analysis
      • The Throughline
      • The Top Line
      • The Forecast
    • Coverage
      • ShowFloor
      • The Arena
  • The Pulse
    • NeuroPulse
    • OrphanPulse
  • Topics
    • By subject
      • Deals
      • Regulatory
      • Market Access
      • Pricing & Reimbursement
      • Legal & Policy
    • By technology
      • Antibody
      • Cell & Gene Tx
      • Drug conjugates
      • AI/ML
      • Digital Health
      • Radiopharma
    • By therapy area
      • Neurology
      • Oncology
      • Rare Diseases
      • Cardio-Metabolic
      • Immunology & Inflammation
      • Orthopaedics
    • By Category
      • Access Read
      • CI read
      • Clinical Read
      • Deal Read
      • Science Read
The FTC Warned 24 Large Healthcare Companies That Following CMS Price Rules Is No Shield Against a Deception Case
The FTC Warned 24 Large Healthcare Companies That Following CMS Price Rules Is No Shield Against a Deception Case
Athithi Verma October 8, 2026
A hospital can meet every CMS posting rule and still face an FTC deception case over the estimate a patient receives.
One Price in Japan, Response-Linked Payments in Australia and No Public Price in China: In Asia-Pacific the Payer Sets the CAR-T Price
One Price in Japan, Response-Linked Payments in Australia and No Public Price in China: In Asia-Pacific the Payer Sets the CAR-T Price
CMS Set December 2027 for Insurers' Prescription Drug Price Files, a Requirement on Hold Since 2021
CMS Set December 2027 for Insurers’ Prescription Drug Price Files, a Requirement on Hold Since 2021
Brussels Chose Two Transcatheter Mitral Valves for Its First Joint Device Assessments, With Only One Country Already Assessing Each
Only one Member State was assessing each valve when Brussels chose them, so the joint report will frame the evidence.
Korea's First Homegrown GLP-1 Cut Weight 9.75% at 40 Weeks, So Hanmi Will Fight Wegovy and Mounjaro on Price and Supply
Korea’s First Homegrown GLP-1 Cut Weight 9.75% at 40 Weeks, So Hanmi Will Fight Wegovy and Mounjaro on Price and Supply
Denmark Said No to a DKK 2.5m CAR-T in January and Yes Once Kite Tied the Price to Response
Denmark Said No to a DKK 2.5m CAR-T in January and Yes Once Kite Tied the Price to Response

Editor’s Pick

Australia Set a Price Lilly Refused, So Lilly Built a Channel Around the PBS

Australia Set a Price Lilly Refused, So Lilly Built a Channel Around the PBS

Rare Disease Produced Two First-Ever Approvals in Two Days, and Both of Them Are Neurology

Rare Disease Produced Two First-Ever Approvals in Two Days, and Both of Them Are Neurology

In Ustekinumab Biosimilars, Approval Stopped Being the Hard Part

In Ustekinumab Biosimilars, Approval Stopped Being the Hard Part

NeuroPulse


NeuroPulse Wk 40: AbbVie Won Approval for Juvmo Three Days Before ICER Met on Its Value

NeuroPulse Wk 40: AbbVie Won Approval for Juvmo Three Days Before ICER Met on Its Value

NeuroPulse Wk 39: Otsuka Opened Early Access the Day Before FUS-ALS Read Out

NeuroPulse Wk 39: Otsuka Opened Early Access the Day Before FUS-ALS Read Out

OrphanPulse


OrphanPulse Wk 40: A First Approval in MCT8 Deficiency, and a Missed Pivotal Headed for Filing

OrphanPulse Wk 40: A First Approval in MCT8 Deficiency, and a Missed Pivotal Headed for Filing

OrphanPulse Wk 39: A 900-Patient Disease Now Has Two Approved Drugs

OrphanPulse Wk 39: A 900-Patient Disease Now Has Two Approved Drugs

DealPulse Signal


DealPulse Signal Wk 39: Telix Paid in Stock and the Platforms Paid in Promises

DealPulse Signal Wk 39: Telix Paid in Stock and the Platforms Paid in Promises

DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Report


DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead

DealFlow H1 2026 M&A Doubles as Upfront Spending Hits $174B

DealFlow H1 2026: M&A Doubles as Upfront Spending Hits $174B

The Beats


DealPulse Signal Wk 39: Telix Paid in Stock and the Platforms Paid in Promises

DealPulse Signal Wk 39: Telix Paid in Stock and the Platforms Paid in Promises

DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week

DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It

DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It

Analysis


Radiopharmaceuticals: sixteen years of deal data on where the field goes next

Radiopharmaceuticals: sixteen years of deal data on where the field goes next

Behind the Headlines How the Leaders Really Performed

Behind the Headlines: How the Leaders Really Performed

Reshaping Pharma by 2027

7 Market Access Trends Reshaping Pharmaย by 2027

Coverage


ADCs Returned 0.46 in Relapsed Disease and 1.15 in the Front Line at WCLC

The ADC Decade Accelerates What to Watch at ASCO 2026

The ADC Decade Accelerates: What to Watch at ASCO 2026

The Briefs

The FTC Warned 24 Large Healthcare Companies That Following CMS Price Rules Is No Shield Against a Deception Case

The FTC Warned 24 Large Healthcare Companies That Following CMS Price Rules Is No Shield Against a Deception Case

Athithi Verma October 8, 2026
One Price in Japan, Response-Linked Payments in Australia and No Public Price in China: In Asia-Pacific the Payer Sets the CAR-T Price

One Price in Japan, Response-Linked Payments in Australia and No Public Price in China: In Asia-Pacific the Payer Sets the CAR-T Price

Athithi Verma October 8, 2026
CMS Set December 2027 for Insurers' Prescription Drug Price Files, a Requirement on Hold Since 2021

CMS Set December 2027 for Insurers’ Prescription Drug Price Files, a Requirement on Hold Since 2021

Athithi Verma October 8, 2026
Brussels Chose Two Transcatheter Mitral Valves for Its First Joint Device Assessments, With Only One Country Already Assessing Each

Only one Member State was assessing each valve when Brussels chose them, so the joint report will frame the evidence.

Athithi Verma October 8, 2026
Korea's First Homegrown GLP-1 Cut Weight 9.75% at 40 Weeks, So Hanmi Will Fight Wegovy and Mounjaro on Price and Supply

Korea’s First Homegrown GLP-1 Cut Weight 9.75% at 40 Weeks, So Hanmi Will Fight Wegovy and Mounjaro on Price and Supply

Athithi Verma October 8, 2026
Denmark Said No to a DKK 2.5m CAR-T in January and Yes Once Kite Tied the Price to Response

Denmark Said No to a DKK 2.5m CAR-T in January and Yes Once Kite Tied the Price to Response

Athithi Verma October 6, 2026
Read More
Synopulse
Contact Us

Explore Synopulse

  • NeuroPulse
  • Deals
  • Market Access
  • Industry Trends
  • Regulatory

About

  • About Synopulse
  • Contact Us
  • Announcements
© 2026 Synopulse • Built with GeneratePress